Table 1.
Baseline patient characteristics
| Everolimus | Sunitinib | ||
|---|---|---|---|
| n = 35 | n = 33 | ||
| Age, yr, median (range) | 58 (23–73) | 60 (28–76) | |
| Gender, male:female | 24:11 | 19:14 | |
| Race | White | 28 | 25 |
| Hispanic | 3 | 5 | |
| Black | 2 | 3 | |
| Prior nephrectomy | 27 | 25 | |
| Histology | Papillary | 13 | 14 |
| Clear cell with sarcomatoid features | 6 | 6 | |
| Chromophobe | 6 | 6 | |
| Translocation | 4 | 3 | |
| Unclassified | 6 | 4 | |
| ECOG performance status | 0 | 15 | 18 |
| 1 | 20 | 15 | |
| MSKCC risk group | Good | 4 | 4 |
| Intermediate | 29 | 29 | |
| Poor | 2 | 0 | |
| IMDC risk group | Good | 4 | 3 |
| Intermediate | 24 | 26 | |
| Poor | 7 | 4 | |
| No. of metastatic disease sites | 1 | 6 | 6 |
| ≥2 | 29 | 27 | |
| Metastatic disease sites | Lung | 17 | 16 |
| Bone | 7 | 11 | |
| Liver | 9 | 7 | |
| Supradiaphragmatic adenopathy | 14 | 15 | |
| Infradiaphragmatic adenopathy | 16 | 16 | |
| Pleural | 1 | 1 | |
| Kidney | 7 | 7 | |
| Renal fossa | 5 | 3 | |
| Pancreas | 0 | 1 | |
| Adrenal | 2 | 2 | |
| Skin | 1 | 0 | |
ECOG= Eastern Cooperative Oncology Group; IMDC = International Metastatic Renal Cell Carcinoma Database Consortium; MSKCC = Memorial Sloan Kettering Cancer Center.